Association of liver enzymes with estimated 10-year cardiovascular disease risk: findings from the Azar cohort study

Earlier studies examining the relationship between liver enzymes and cardiovascular disease (CVD) risk have produced conflicting results, and there is limited evidence demonstrating that liver enzymes influence the Framingham Risk Score (FRS). This cross-sectional study investigates whether liver enzymes are assocaited with the 10-year FRS in a large population sample from the AZAR cohort. This study utilized a large sample of 14,219 individuals aged 35 to 70 years from the AZAR cohort. Demographic characteristics, physical activity levels, liver enzyme levels, and anthropometric variables were assessed. The 10-year Framingham Risk Score (FRS) was calculated according to the Adult Treatment Panel III (ATP III) guidelines. Participants were categorized into two groups for analysis :those with a low (<10%) and those with intermediate to high risk (>=10%).​ Binary logistic regression was employed to examine the relationship between liver enzymes and the 10-year risk of cardiovascular disease (CVD), adjusting for confounding factors. After adjusting for confounding factors, the second and third tertiles of four liver enzymes were associated with higher odds of an FRS ≥ 10%, compared with the first tertile. Among the liver enzymes examined, GGT showed the strongest association with an FRS ≥ 10%, with adjusted odds ratios (AORs) of 2.67 (95% CI: 2.36–3.03; p < 0.001) for the second tertile and 4.10 (95% CI: 3.63–4.64; p < 0.001) for the third tertile, compared to the first tertile. Although AST was also significantly associated with an FRS ≥ 10%, the strength of this association was weaker than that observed for the other liver enzymes. For AST, the association was more pronounced in the third tertile than in the second tertile. In this cross-sectional study, all four liver enzymes were significantly associated with the 10-year Framingham Risk Score (FRS), with GGT showing the strongest association. Based on these findings, assessing liver enzyme levels alongside other clinical factors may help identify individuals with an elevated estimated risk of cardiovascular disease (CVD).

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-11-12
DOI
https://doi.org/10.1186/s12876-026-05512-y
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of liver enzymes with estimated 10-year cardiovascular disease risk: findings from the Azar cohort study

Mohammad Safari, Neda Gilani, Amin Sadrazar, Elnaz Faramarzi et al.
BMC Gastroenterology
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Association of liver enzymes with estimated 10-year cardiovascular disease risk: findings from the Azar cohort study

Mohammad Safari, Neda Gilani, Amin Sadrazar, Elnaz Faramarzi, Mohammad amin Mansoori, Sina Hamzezadeh, Sina Vafadar
article en

Abstract

Earlier studies examining the relationship between liver enzymes and cardiovascular disease (CVD) risk have produced conflicting results, and there is limited evidence demonstrating that liver enzymes influence the Framingham Risk Score (FRS). This cross-sectional study investigates whether liver enzymes are assocaited with the 10-year FRS in a large population sample from the AZAR cohort. This study utilized a large sample of 14,219 individuals aged 35 to 70 years from the AZAR cohort. Demographic characteristics, physical activity levels, liver enzyme levels, and anthropometric variables were assessed. The 10-year Framingham Risk Score (FRS) was calculated according to the Adult Treatment Panel III (ATP III) guidelines. Participants were categorized into two groups for analysis :those with a low (<10%) and those with intermediate to high risk (>=10%).​ Binary logistic regression was employed to examine the relationship between liver enzymes and the 10-year risk of cardiovascular disease (CVD), adjusting for confounding factors. After adjusting for confounding factors, the second and third tertiles of four liver enzymes were associated with higher odds of an FRS ≥ 10%, compared with the first tertile. Among the liver enzymes examined, GGT showed the strongest association with an FRS ≥ 10%, with adjusted odds ratios (AORs) of 2.67 (95% CI: 2.36–3.03; p < 0.001) for the second tertile and 4.10 (95% CI: 3.63–4.64; p < 0.001) for the third tertile, compared to the first tertile. Although AST was also significantly associated with an FRS ≥ 10%, the strength of this association was weaker than that observed for the other liver enzymes. For AST, the association was more pronounced in the third tertile than in the second tertile. In this cross-sectional study, all four liver enzymes were significantly associated with the 10-year Framingham Risk Score (FRS), with GGT showing the strongest association. Based on these findings, assessing liver enzyme levels alongside other clinical factors may help identify individuals with an elevated estimated risk of cardiovascular disease (CVD).

BMC Gastroenterology
Tabriz University of Medical Sciences (IR)
Good health and well-being
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon